Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients
Background: Acute kidney injury (AKI) is highly prevalent in critical COVID-19 patients. The diagnosis and staging of AKI are based on serum creatinine (sCr) and urinary output criteria, with limitations in the functional markers. New cell-cycle arrest biomarkers [TIMP2]*[IGFBP7] have been proposed...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/2/317 |
| _version_ | 1827626773252145152 |
|---|---|
| author | Massimiliano Greco Silvia De Rosa Fabian Boehm Sofia Spano Romina Aceto Antonio Voza Francesco Reggiani Marta Calatroni Gianluca Castellani Elena Costantini Gianluca Villa Maurizio Cecconi |
| author_facet | Massimiliano Greco Silvia De Rosa Fabian Boehm Sofia Spano Romina Aceto Antonio Voza Francesco Reggiani Marta Calatroni Gianluca Castellani Elena Costantini Gianluca Villa Maurizio Cecconi |
| author_sort | Massimiliano Greco |
| collection | DOAJ |
| description | Background: Acute kidney injury (AKI) is highly prevalent in critical COVID-19 patients. The diagnosis and staging of AKI are based on serum creatinine (sCr) and urinary output criteria, with limitations in the functional markers. New cell-cycle arrest biomarkers [TIMP2]*[IGFBP7] have been proposed for early detection of AKI, but their role in critically ill COVID-19 patients is poorly understood. Methods: We conducted an observational study to assess the performance of [TIMP2]*[IGFBP7] for the detection of AKI in critical COVID-19 patients admitted to our intensive care unit (ICU). We sampled urinary [TIMP2]*[IGFBP7] levels at ICU admission, 12 h, 24 h, and 48 h, and compared the results to the development of AKI, as well as baseline and laboratory data. Results: Forty-one patients were enrolled. The median age was 66 years [57–72] and most were males (85%). Thirteen patients (31.7%) developed no/mild stage AKI, 19 patients (46.3%) moderate AKI, and nine patients (22.0%) severe AKI. The ICU mortality was 29.3%. sCr levels in the Emergency Department or at ICU admission were not significantly different according to AKI stage. [TIMP-2]*[IGFBP-7] urinary levels were elevated in severe AKI at 12 h after ICU admission, but not at ICU admission or 24 h or 48 h after ICU admission. Conclusion: Urinary biomarkers [TIMP-2]*[IGFBP-7] were generally increased in this population with a high prevalence of AKI, and were higher in patients with severe AKI measured at 12 h from ICU admission. Further studies are needed to evaluate the best timing of these biomarkers in this population. |
| first_indexed | 2024-03-09T13:02:16Z |
| format | Article |
| id | doaj.art-e924ef3dd5b04c89a17774cc21fff926 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-09T13:02:16Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-e924ef3dd5b04c89a17774cc21fff9262023-11-30T21:53:48ZengMDPI AGDiagnostics2075-44182023-01-0113231710.3390/diagnostics13020317Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 PatientsMassimiliano Greco0Silvia De Rosa1Fabian Boehm2Sofia Spano3Romina Aceto4Antonio Voza5Francesco Reggiani6Marta Calatroni7Gianluca Castellani8Elena Costantini9Gianluca Villa10Maurizio Cecconi11Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, ItalyCentre for Medical Sciences—CISMed, University of Trento, Via S. Maria Maddalena 1, 38122 Trento, ItalyDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, ItalyDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, ItalyDepartment of Anesthesia and Intensive Care, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, ItalyDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, ItalyDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, ItalyDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, ItalyDepartment of Anesthesia and Intensive Care, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, ItalyDepartment of Anesthesia and Intensive Care, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, ItalyDepartment of Health Sciences, Section of Anesthesia, Intensive Care and Pain Medicine, University of Florence, 50121 Florence, ItalyDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, ItalyBackground: Acute kidney injury (AKI) is highly prevalent in critical COVID-19 patients. The diagnosis and staging of AKI are based on serum creatinine (sCr) and urinary output criteria, with limitations in the functional markers. New cell-cycle arrest biomarkers [TIMP2]*[IGFBP7] have been proposed for early detection of AKI, but their role in critically ill COVID-19 patients is poorly understood. Methods: We conducted an observational study to assess the performance of [TIMP2]*[IGFBP7] for the detection of AKI in critical COVID-19 patients admitted to our intensive care unit (ICU). We sampled urinary [TIMP2]*[IGFBP7] levels at ICU admission, 12 h, 24 h, and 48 h, and compared the results to the development of AKI, as well as baseline and laboratory data. Results: Forty-one patients were enrolled. The median age was 66 years [57–72] and most were males (85%). Thirteen patients (31.7%) developed no/mild stage AKI, 19 patients (46.3%) moderate AKI, and nine patients (22.0%) severe AKI. The ICU mortality was 29.3%. sCr levels in the Emergency Department or at ICU admission were not significantly different according to AKI stage. [TIMP-2]*[IGFBP-7] urinary levels were elevated in severe AKI at 12 h after ICU admission, but not at ICU admission or 24 h or 48 h after ICU admission. Conclusion: Urinary biomarkers [TIMP-2]*[IGFBP-7] were generally increased in this population with a high prevalence of AKI, and were higher in patients with severe AKI measured at 12 h from ICU admission. Further studies are needed to evaluate the best timing of these biomarkers in this population.https://www.mdpi.com/2075-4418/13/2/317acute kidney injurycritically illCOVID-19ARDS[TIMP2]*[IGFBP7]renal replacement therapy |
| spellingShingle | Massimiliano Greco Silvia De Rosa Fabian Boehm Sofia Spano Romina Aceto Antonio Voza Francesco Reggiani Marta Calatroni Gianluca Castellani Elena Costantini Gianluca Villa Maurizio Cecconi Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients Diagnostics acute kidney injury critically ill COVID-19 ARDS [TIMP2]*[IGFBP7] renal replacement therapy |
| title | Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients |
| title_full | Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients |
| title_fullStr | Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients |
| title_full_unstemmed | Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients |
| title_short | Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients |
| title_sort | kinetics of the cell cycle arrest biomarkers timp2 and igfbp7 for the diagnosis of acute kidney injury in critically ill covid 19 patients |
| topic | acute kidney injury critically ill COVID-19 ARDS [TIMP2]*[IGFBP7] renal replacement therapy |
| url | https://www.mdpi.com/2075-4418/13/2/317 |
| work_keys_str_mv | AT massimilianogreco kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT silviaderosa kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT fabianboehm kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT sofiaspano kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT rominaaceto kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT antoniovoza kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT francescoreggiani kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT martacalatroni kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT gianlucacastellani kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT elenacostantini kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT gianlucavilla kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT mauriziocecconi kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients |